Entrepreneur UK's London 100: Creditspring
With living costs remaining high and credit options decreasing, millions of people across the UK face financial struggles. A quarter (26%) of people say this is the most financially unstable they've ever been whilst over one in ten (13%) are reliant on credit to pay their bills.
FCA-regulated responsible lender Creditspring launched in 2016, providing a unique way for customers to access loans – through subscriptions. This approach makes lending fairer, safer and easier to understand for borrowers. Creditspring's innovative model enables members to pay a small, fixed monthly membership fee and can access two no-interest loans per year. This approach means that borrowers can see exactly how much they are going to pay the moment they apply, without hidden charges or late fees and no risk of falling into debt spirals.
Members also have access to a range of additional support solutions that can boost their financial resilience, from improving their credit score to assessing their eligibility for support schemes via its Benefits Finder, a tool that unlocks access to unclaimed government benefits. Since launch, Creditspring has found over £2b in unclaimed benefits with members claiming an average of £977 in monthly government support.
During 2024, Creditspring provided over £200m in financial support to borrowers, a 63% increase on the £127m lent in 2023. Across 2024, Creditspring's revenue increased by over 80% (from almost £18.2m to over £33.2m) as it became profitable in Q3, continued to scale and provide increased responsible credit options.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
JD.Com to acquire Ceconomy
(Reuters) -China's said on Wednesday it will acquire German electronics retailer Ceconomy at 4.60 euros per share. Reuters reported the deal earlier on Wednesday. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
First Look: Profitablity measures at C.H. Robinson point higher in 2Q
C.H. Robinson CEO Dave Bozeman (NASDAQ: CHRW), in releasing the company's second quarter earnings, said it represented 'six consecutive quarters of consistent outperformance through the disciplined execution of the strategy that we shared at our 2024 investor day.' The revenue figure for the company was down, in part because of the divestiture of the company's European Surface Transportation business, which housed the basic truck brokerage activities of the company. The decline was 7.7%. The figure for gross profits was up 0.4% to $679.6 The adjusted operating margin was up 520 bps to 31.1%. That also marked a significant sequential jump from 26.3%. Income from operations was up 21.2% year on year, to $215.9 million. In the first quarter, that figure was about $177 million. C.H. Robinson continues to slash headcount. Total average employee headcount in the second quarter was 12,858, down 11.2% from a year earlier. In the first quarter, that number was 13,347. The North American Surface Transport sector, which contains its brokerage operations, saw its profitability rise even as it produced less revenue. Total revenue in NAST was down 2.4% for the quarter compared to the year earlier period. But adjusted gross profits rose 3% year-on-year, and income from operations were up 16.2%. Average headcount at NAST was 5,283, down from 5,868 a year earlier. It was actually up by 3 from the first quarter. Adjusted net income of $1.29/share was up 12.2% from a year ago, and was 13 cts/share more than the consensus estimate, according to SeekingAlpha. Revenue of $4.14 billion was short of consensus estimate by $40 million. C.H. Robinson's stock is up 9.3% in the last 52 weeks. Post-market trading was light but suggested a positive reaction to the report. C.H. Robinson closed the day at $97.65, with reports afterward of the stock price hitting the $100 mark. More articles by John Kingston Sequential numbers at diversified trucking operator TFI International may mark a turnaround Ryder's used vehicle numbers show a bullish corner: tractor sales Five takeaways from the State of Freight for July: What earnings and the indices are saying about the market The post First Look: Profitablity measures at C.H. Robinson point higher in 2Q appeared first on FreightWaves. Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
AstraZeneca increasing focus on US market, as it is 'first to provide access to patients': CFO
AstraZeneca (AZN) is shifting its focus to the US, calling itself an "American company" on Tuesday as it ramps up manufacturing and proposes price cuts for the US market. CEO Pascal Soriot told reporters Tuesday that the company, which reported its best quarter to date on the same day, "We are a very American company. We are global, but we are certainly very much rooted and present in the US." Tuesday's comment comes as the UK-based and UK-listed company is reportedly considering moving its main stock market listing to New York. In addition, the company recently announced $50 billion in manufacturing commitments in the US — including a brand-new facility in Virginia — and stated its goal of having 50% of its revenue come from the US by 2030. AstraZeneca's top-selling drugs include cancer drug Tagrisso and diabetes drug Farxiga. CFO Aradhana Sarin told Yahoo Finance that the moves are independent of Trump's tariff threats of up to 200% on the pharmaceutical industry. "We have been thinking about our strategic manufacturing — this probably goes back 3 or 4 years," she said. "So, post-COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains." "This new facility [in Virginia] that we announced was part of the plan anyway," she added. "But that's separate, it's nothing to do with tariffs. It's actually based on the demand that we see potentially for our new cardiovascular medicine." And there are other reasons why the market is more appealing — including how quickly products reach patients in the US versus other countries. "When new therapies come ... the US market is almost the first to provide access to patients. Physicians ... are really into looking at the data," Sarin said, explaining why the US market is more appealing to pharma than other markets. AstraZeneca is also focused on other strategies that appeal to the US government, including price cuts. It sent a proposal to the US government on price reductions for some of its drugs. The proposal is under review, Soriot said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
